Más contenido relacionado



  1. Probuphine for treatment of opioid dependency Presented By: GOLAP Sk. Roll no:- 19301913032 Reg no:- 131930210032 4th Year, Semester: 7th Bengal School Of Technology, (A college of Pharmacy) Hooghly ,West Bengal 2016
  2. OPOID DEPENDENCY Opioid dependency is a medical condition that is characterized by the compulsive use of opioids. Opioids include substances:  Morphine Heroin Codeine Oxycodone
  3. TYPES OF DOSAGE FORM AVAILABLE Tablet Petazocine 5 mg tab Injection Naloxone 0.4-0.8 mg inj Sublingual Buprenorphine 0.2-0.4 mg subli Implant Buprenorphine 74.2 mg
  4. Implants are the drug delivery systems which act as reservoir of loaded drug and deliver it over a period of time in a controlled manner upon insertion into the body.  INTRAMUSCULAR  INTRACARNIAL  SUBDERMAL
  5. Probuphine (buprenorphine; ethylene vinyl acetate) Implantable formulation of buprenorphine Properties of Individual Rods • 80 mg BPN & ethylene vinyl acetate • 26mm long & 2.5mm diameter rod • Sustained release up to 6 month
  6. General instruction: Each dose consist of 4 implants inserted subdermally in the inner side of the upper arm. Implant are intended to be in place for 6 month & Removes implants by the end of the 6 month. Dose & strengths: Probuphine is a sterile ,single, off white ,soft, flexible ,rod shape ethylene vinyl acetate[EVA] implant .74.2mg probuphine.
  7. *
  8. Mechanism of Action: PROBUPHINE implants contain buprenorphine. Buprenorphine is a partial agonist at the mu opioid receptor and an antagonist at the kappa- opioid receptor.
  9. ADVERSE REACTIONS Implant site pain Headache Constipation Back pain Allergic reaction Vomiting Infection at implant site
  10. Long term treatment One time invest Very effective as rehabitation  Best choice for drug addicted persons  Potential selected chronic diseases with low dose Costly Skilled personnel required For insertion & removal Pain, irritation, swelling Implant comes out by itself
  11. Reference: 1. Breasted JG. Ancient Records of Egypt. University of Chicago Oriental Institute Publications, Vol. III, P. 217. University of Chicago Press, 1930. Kiang TK, Epsom MH, Chang TK. UDP glucuronos yltransferase and clinical drug-drug interactions. Pharmaco There 2005; 106:97-132 Behar, K.L., et al., 1999. Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. American Journal of Psychiatry 156(6):952-954 Breiter, H.C., et al., 1997. Acute effects of cocaine on human brain activity and emotion. Neuron 19(3):591- 611 Judd, L.L., et al., 1998. Effective medical treatment of opiate addiction. Journal of the American Medical Association 280(22):1936-1943  Ling W, Mooney L, Zhao M, et al. Selective review and commentary on emerging pharmacotherapies  Rosenthal RN, Ling W, Casadonte P, et al. Buprenorphine implants for treatment of opioid dependence: Randomized comparison to placebo and sublingual buprenorphine/ naloxone. Addiction, 2013;108(12  ECRI Institute. AHRQ Healthcare Horizon Scanning System Potential High-Impact Interventions: Priority Area 14: Substance Abuse. Prepared by ECRI Institute for AHRQ under Contract No. HHSA290201000006C. Rockville, MD: Agency for Healthcare Research and Quality; December 2013 1. Rosenthal RN, Lowell MR, Kim S, et al. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial. JAMA. 2016;19:282-290. Braeburn Pharma. Probuphine (buprenorphine) implant for sub dermal administration. Prescribing Information. Reference ID: 3937415. Princeton, NJ: Braeburn Pharma; revised May 2016.